Positions

Selected Publications

Academic Article

Year Title Altmetric
2020 The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma.  Cancer Letters.  468:48-58. 2020
2019 The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors.  EBioMedicine.  44:419-430. 2019
2018 FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer.  Cancer Letters.  436:75-86. 2018
2018 Pediatric anaplastic embryonal rhabdomyosarcoma: Targeted therapy guided by genetic analysis and a patient-derived xenograft study.  Frontiers in Oncology.  7. 2018
2016 The tumor-associated glycosyltransferase ST6Gal-I regulates stem cell transcription factors and confers a cancer stem cell phenotype.  Cancer Research.  76:3978-3988. 2016
2013 N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells.  BMC Cancer.  13. 2013
2009 Cell adhesion molecules as targets for therapy of neuroblastoma..  Cancer Biology and Therapy.  8:306-311. 2009
2007 Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma.  Cancer Research.  67:22-25. 2007
2005 Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11..  Chemico-Biological Interactions.  157-158:247-252. 2005
2005 Development of prodrugs for enzyme-mediated, tumor-selective therapy. 2005
2003 Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism.  Bioorganic and Medicinal Chemistry.  11:3237-3244. 2003

Education And Training

  • Doctor of Philosophy in Pharmacology, Florida Agricultural & Mechanical University 2001

    • Full Name

  • Karina Yoon